These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 18559790

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib.
    Cicek D, Kandi B, Dagli FA, Karaoglu A, Haligur BD.
    Clin Drug Investig; 2008; 28(12):803-7. PubMed ID: 18991474
    [Abstract] [Full Text] [Related]

  • 24. Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.
    Ide S, Soda H, Hakariya T, Takemoto S, Ishimoto H, Tomari S, Sawai T, Nagashima S, Furukawa M, Nakamura Y, Kohno S.
    Lung Cancer; 2010 Feb; 67(2):248-50. PubMed ID: 19897274
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
    Flaherty KT.
    Cancer; 2010 Jan 01; 116(1):4-7. PubMed ID: 19890962
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J, Escudier B, Wechsler J, Spatz A, Robert C.
    Arch Dermatol; 2008 Jul 01; 144(7):886-92. PubMed ID: 18645140
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
    Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K, Escudier B.
    Ann Oncol; 2011 Aug 01; 22(8):1812-23. PubMed ID: 21324953
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Array of cutaneous adverse effects associated with sorafenib.
    Kong HH, Turner ML.
    J Am Acad Dermatol; 2009 Aug 01; 61(2):360-1. PubMed ID: 19615549
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.